Protective role for plasmid DNA-mediated VIP gene transfer in non-obese diabetic mice

Annals of the New York Academy of Sciences

Volumn 1070, Issue , 2006, Pages 337-341

  Herrera, Juan Luis ^a   Fernández Montesinos, Rafael ^a   González Rey, Elena ^b   Delgado, Mario ^b   Pozo, David ^a,c  

^a UNIVERSITY OF SEVILLE   (Spain)

^b INSTITUTO DE PARASITOLOGÍA Y BIOMEDICINA LÓPEZ NEYRA   (Spain)

^c UNIVERSITY OF SEVILLE   (Spain)

Author keywords

Diabetes; Gene delivery; Neuroimmunology; Vasoactive intestinal peptide

Indexed keywords

CYCLOPHOSPHAMIDE; DNA VACCINE; PLASMID DNA; VASOACTIVE INTESTINAL POLYPEPTIDE; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; AUTOIMMUNE DISEASE; CONFERENCE PAPER; CYTOKINE PRODUCTION; DIABETES MELLITUS; FEMALE; GENE DELIVERY SYSTEM; GENE TRANSFER; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOREGULATION; INFLAMMATION; METHODOLOGY; MOUSE; MOUSE STRAIN; NONHUMAN; OBESITY; PLASMID; TH1 CELL; VIRUS INFECTION;

EID: 33746421875     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1317.041     Document Type: Conference Paper

References (12)

1. RAZ, I., R. ELDOR & Y. NAPARSTEK. 2005. Immune modulation for prevention of type 1 diabetes mellitus. Trends Biotechnol. 23: 128-134.
2. BEYAN, H. et al. 2003. A role for innate immunity in type 1 diabetes? Diabetes Metab. Res. Rev. 19: 89-100.
3. KUKREJA, A. et al. 2002. Multiple immuno-regulatory defects in type-1 diabetes. J. Clin. Invest. 109: 131-140.
4. ATKINSON, M.A. & E.H. LEITER. 1999. The NOD mouse model of type 1 diabetes: as good as it gets? Nat. Med. 5: 601-604.
5. GALLEGOS, A.M. & M.J. BEVAN. 2004. Driven to autoimmunity: the nod mouse. Cell 117: 149-151.
6. GUERRERO, J. et al. 1981. Interaction of vasoactive intestinal peptide with human blood mononuclear cells. Mol. Cell Endocrinol. 21: 151-160.
7. O'DORISIO, M.S. et al. 1981. Vasoactive intestinal polypeptide modulation of lymphocyte adenylate cyclase. J. Immunol. 127: 2551-2554.
8. GOMARIZ, R. et al. 1990. Demonstration of immunoreactivity vasoactive intestinal peptide (IR-VIP) and somatostatin (IR-SOM) in rat thymus. Brain Behav. Immun. 4: 151-161.
9. DELGADO, M. et al. 2002. Vasoactive intestinal peptide in the immune system: potential therapeutic role in inflammatory and autoimmune diseases. J. Mol. Med. 80: 16-24.
10. GANEA, D. & M. DELGADO. 2002. Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating polypeptide (PACAP) as modulators of both innate and adaptive immunity. Crit. Rev. Oral Biol. Med. 13: 229-237.
11. DELGADO, M., D. POZO & D. GANEA. 2004. The significance of vasoactive intestinal peptide in immunomodulation. Pharmacol. Rev. 56: 249-290.
12. POZO, D. & M. DELGADO. 2004. The many faces of VIP in neuroimmunology: a cytokine rather a neuropeptide? FASEB J. 18: 1325-1334.